Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 634-640

  Martens, A C M ^a   Hagenbeek, A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amifostine; Bone marrow transplantation; Dose escalation; Leukaemia

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG MEGADOSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; WHOLE BODY RADIATION;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RADIATION-PROTECTIVE AGENTS; RATS; RATS, INBRED STRAINS; SURVIVAL ANALYSIS; WHOLE-BODY IRRADIATION;

EID: 0033118645     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00412-2     Document Type: Article

References (48)

1. Löwenberg B., Verdonck L.J., Dekker A., et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J. Clin. Oncol. 8:1990;287-294.
2. Truitt R.L., Atasoylu A.A. Impact of pretransplant conditioning and donor T-cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity and tolerance after bone marrow transplantation. Blood. 77:1991;2515-2523.
3. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85-86.
4. Lewis C. A review of the use of chemoprotectants in cancer chemotherapy. Drug Safety. 11:1994;153-162.
5. 50/30 doses. Radiation Res. 44:1970;621-628.
6. Grdina D.J., Carnes Grahn D., Sigdestad C.P. Protection against late effects of radiation by S-2[3-aminopropyl-amino]ethylphosphorothioic acid. Cancer Res. 51:1991;4125-4130.
7. Floersheim G.L., Christ A., Koenig R., Racine C., Gudat F. Radiation-induced lymphoid tumors and radiation lethality are inhibited by combined treatment with small doses of zinc aspartate and WR 2721. Int. J. Cancer. 52:1992;604-608.
8. Treskes M., Nijtmans L., Fichtinger-Schepman A.M., van der Vijgh W.J. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res. 12:1992;2261-2265.
9. Treskes M., Boven E., van de Loosdrecht A.A., et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur. J. Cancer. 30:1994;183-187.
10. Treskes M., van der Vijgh W.J. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. [Review]. Cancer Chemother. Pharmacol. 33:1993;93-106.
11. Adamson P.C., Balis F.M., Belasco J.E., et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 55:1995;4069-4072.
12. DeNeve W.J., Everett C.K., Suminski J.E., Valeriote F.A. Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res. 48:1988;6002-6005.
13. Twentyman P.R. Modification of tumor and host response to cyclophosphamide by misonidasole and by WR-2721. Br. J. Cancer. 43:1981;745-755.
14. Herrera J.L., Vigneulle R.M., Gage T., MacVittie T.J., Nold J.B., Dubois A. Effect of radiation and radioprotection on small intestinal function in canines. Dig. Dis. Sci. 40:1995;211-218.
15. Halberg F.E., LaRue S.M., Rayner A.A., et al. Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;1241-1246.
16. Delaney J.P., Bonsack M.E., Felemovicius I. Radioprotection of the rat small intestines with topical WR-2721. Cancer. 74:1994;2379-2384.
17. Schor N.F. A neurologist's approach to neuroblastoma. J. Child. Neurol. 7:1992;93-98.
18. Travis E.L., Meistrich M.L., Finch-Meimeyer M.V., Watkins T.L., Kiss I. Late functional and biochemical changes in mouse lung after irradiation. Differential effects of WR2721. Radiat. Res. 103:1985;219-231.
19. McCulloch W., Scheffler B.J., Schein P.S. New protective agents for bone marrow in cancer therapy. Cancer Invest. 9:1991;279-287.
20. Phillips TL, Yuhas JM, Wasserman TH. Differential protection against alkylating agent injury in tumors and normal tissues. In Nygaard OF, Simic MG, eds. Radioprotectors and Anticarcinogens. New York, Academic Press, 1983, 735-748.
21. Wasserman T.H. Radiotherapeutic studies with amifostine (Ethyol) [Review]. Semin. Oncol. 21:1994;21-25.
22. Patchen M.L. Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animal models. Eur. J. Cancer. 31A:(Suppl):1995;S17-S21.
23. Constine L.S., Zagars G., Rubin P.R., Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1505-1508.
24. Meagher R.C., Rothman S.A., Paul P., Koberna P., Willmer C., Baucco P.A. Purging of small cell lung cancer cells from human bone marrow using Ethiofos (WR-2721) and light activated Merocyanine 540 phototreatment. Cancer Res. 49:1989;3637-3641.
25. Shpall E.J., Stemmer S.M., Hami L., et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 83:1994;3132-3137.
26. Douay L., Hu C., Giarratana M-C., Gorin N-C. Amifostine (WR2721) protects normal haemopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukemic effects. Eur. J. Cancer. 31A:(Suppl):1995;S14-S16.
27. Douay L., Hu C., Giarratana M.C., et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 86:1995;2849-2855.
28. Peters G.J., van der Vijgh W.J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur. J. Cancer. 31A:(Suppl: S):1994;1-7.
29. Calabro-Jones P.M., Fahey R.C., Smoluk G.D., Ward J.F. Alkaline phosphatase promotes radioprotection and accumulation of WRA-1065 in V79-171 cells incubated in medium containing WR2721. Int. J. Radiat. Biol. 47:1985;23-27.
30. Schuchter L.M., Luginbuhl W.E., Meropol N.J. The current status of toxicity protectants in cancer therapy. Semin Oncol. 19:1992;742-751.
31. Yuhas J.M., Spellman J.M., Jordan S.W., Pardini M.C., Afzal S.M.H., Culo F. Treatment of tumors with the combination of WR-2721 and cis-dicholordiammineplatinum (II) or cyclophosphamide. Br. J. Cancer. 42:1980;574-585.
32. Valeriote F., Grates H.E. Potentiation of nitrogen mustard cytotoxicity to leukemia cells by sulfur-containing compounds administered in vivo. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1165-1169.
33. Martens A.C.M., van Bekkum D.W., Hagenbeek A. The BN acute myelocytic leukemia model. A model for studying human acute myelocytic leukemia (AML). Leukaemia. 4:1990;241-257.
34. Hagenbeek A., Martens A.C.M. High dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model. Eur. J. Cancer Clin. Oncol. 18:1982;763-769.
35. Hagenbeek A., Martens A.C.M. The efficacy of high dose cyclophosphamide in combination with total body irradiation in the treatment of acute myelocytic leukemia. Studies in a relevant rat model (BNML). Cancer Res. 43:1983;408-412.
36. Schultz FW, Martens ACM, Hagenbeek A. A mathematical model for leukemia (re-) growth in the rat. In Eisenfeld J, Witten M, eds. Imacs Transactions on Scientific Computing-'85, 5, Modelling of Biomedical Systems. North Holland, Amsterdam, 1986, 41-46.
37. Sterling Research Group. An assessment of the toxicity of WR-2721 in rats following daily intravenous administration for 28 days. Report Number 3930890ATX-0004-59042, 1989.
38. StatView. Abacus Concepts, Berkeley, California, U.S.A.
39. Hagenbeek A, Martens ACM. Minimal residual disease in acute leukaemia: preclinical studies in a relevant rat leukaemia model (BNML). In Proctor SJ, ed. Bailliére's Clinical Haematology, Vol. 4, No. 3, 1991, 609-635.
40. Wasserman T.H., Phillips T.L., Ross G., Kane L.J. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFU-S by WR2721. Cancer Clin. Trials. 4:1981;3-6.
41. Taylor C.W., Wang L.M., List A.F., et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur. J. Cancer. 33:1997;1693-1698.
42. List A.F., Brasfield R., Heaton R., et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364-3369.
43. Jones R.J., Wagner J.E., Celano P., Zicha M.S., Sharkis S.J. Separation of pluripotent hematopoietic stem cells from spleen colony forming cells. Nature. 347:1990;188.
44. Van der Sluijs J.P., De Jong J.P., Brons N.H.C., Ploemacher R.E. Marrow repopulating cells but not CFU-S establish long term in vitro hematopoiesis on a marrow derived stromal layer. Exp. Hematol. 18:1990;893.
45. Breems D.A., Blokland E.A.W., Neben S., Ploemacher R.E. Frequency analysis of human primitive haematopoietic subsets using a cobblestone area forming cell assay. Leukemia. 8:1994;1095-1104.
46. Eaves C.J., Sutherland H.J., Udomsakdi C., Lansdorp P.M., Szilvassy S.I. The human hematopoietic stem cell in vitro and in vivo. Blood Cells. 18:1992;301-307.
47. Fichtner I., Lemm M., Becker M., Berthold F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs. 8:1997;174-181.
48. Aviles A., Diaz M.J., Talavera A., Garcia E.L., Guzman R., Nambo M.J. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur. J. Cancer. 33:1997;1323-1325.